Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues

被引:201
作者
Parra, Edwin R. [1 ]
Uraoka, Naohiro [1 ]
Jiang, Mei [1 ]
Cook, Pamela [1 ]
Gibbons, Don [2 ]
Forget, Marie-Andree [3 ]
Bernatchez, Chantale [3 ]
Haymaker, Cara [3 ]
Wistuba, Ignacio I. [1 ]
Rodriguez-Canales, Jaime [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Melanoma Med Oncol, Houston, TX 77030 USA
来源
SCIENTIFIC REPORTS | 2017年 / 7卷
关键词
TYRAMIDE SIGNAL AMPLIFICATION; PD-1; BLOCKADE; NIVOLUMAB; RESPONSES; ANTIBODY; SAFETY; CELLS; IMMUNOHISTOCHEMISTRY; INFILTRATION; ANTI-PD-1;
D O I
10.1038/s41598-017-13942-8
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Immune-profiling is becoming an important tool to identify predictive markers for the response to immunotherapy. Our goal was to validate multiplex immunofluorescence (mIF) panels to apply to formalin-fixed and paraffin-embedded tissues using a set of immune marker antibodies, with the Opal (TM) 7 color Kit (PerkinElmer) in the same tissue section. We validated and we described two panels aiming to characterize the expression of PD-L1, PD-1, and subsets of tumor associated immune cells. Panel 1 included pancytokeratin (AE1/AE3), PD-L1, CD4, CD8, CD3, CD68, and DAPI, and Panel 2 included pancytokeratin, PD-1, CD45RO, granzyme B, CD57, FOXP3, and DAPI. After all primary antibodies were tested in positive and negative controls by immunohistochemistry and uniplex IF, panels were developed and simultaneous marker expressions were quantified using the Vectra 3.0 (TM) multispectral microscopy and image analysis InForm (TM) 2.2.1 software (PerkinElmer). These two mIF panels demonstrated specific co-localization in different cells that can identify the expression of PD-L1 in malignant cells and macrophages, and different T-cell subpopulations. This mIF methodology can be an invaluable tool for tumor tissue immune-profiling to allow multiple targets in the same tissue section and we provide that is accurate and reproducible method when is performed carefully under pathologist supervision.
引用
收藏
页数:11
相关论文
共 25 条
  • [1] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    Ansell, Stephen M.
    Lesokhin, Alexander M.
    Borrello, Ivan
    Halwani, Ahmad
    Scott, Emma C.
    Gutierrez, Martin
    Schuster, Stephen J.
    Millenson, Michael M.
    Cattry, Deepika
    Freeman, Gordon J.
    Rodig, Scott J.
    Chapuy, Bjoern
    Ligon, Azra H.
    Zhu, Lili
    Grosso, Joseph F.
    Kim, Su Young
    Timmerman, John M.
    Shipp, Margaret A.
    Armand, Philippe
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) : 311 - 319
  • [2] THE USE OF CATALYZED REPORTER DEPOSITION AS A MEANS OF SIGNAL AMPLIFICATION IN A VARIETY OF FORMATS
    BOBROW, MN
    LITT, GJ
    SHAUGHNESSY, KJ
    MAYER, PC
    CONLON, J
    [J]. JOURNAL OF IMMUNOLOGICAL METHODS, 1992, 150 (1-2) : 145 - 149
  • [3] Nivolumab: targeting PD-1 to bolster antitumor immunity
    Brahmer, Julie R.
    Hammers, Hans
    Lipson, Evan J.
    [J]. FUTURE ONCOLOGY, 2015, 11 (09) : 1307 - 1326
  • [4] Dong HD, 2002, NAT MED, V8, P793, DOI 10.1038/nm730
  • [5] Innate and adaptive immune cells in the tumor microenvironment
    Gajewski, Thomas F.
    Schreiber, Hans
    Fu, Yang-Xin
    [J]. NATURE IMMUNOLOGY, 2013, 14 (10) : 1014 - 1022
  • [6] B7-H1/PD-1 Blockade Therapy in Non-Small Cell Lung Cancer Current Status and Future Direction
    Gettinger, Scott
    Herbst, Roy S.
    [J]. CANCER JOURNAL, 2014, 20 (04) : 281 - 289
  • [7] Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer
    Gettinger, Scott N.
    Horn, Leora
    Gandhi, Leena
    Spigel, David R.
    Antonia, Scott J.
    Rizvi, Naiyer A.
    Powderly, John D.
    Heist, Rebecca S.
    Carvajal, Richard D.
    Jackman, David M.
    Sequist, Lecia V.
    Smith, David C.
    Leming, Philip
    Carbone, David P.
    Pinder-Schenck, Mary C.
    Topalian, Suzanne L.
    Hodi, F. Stephen
    Sosman, Jeffrey A.
    Sznol, Mario
    McDermott, David F.
    Pardoll, Drew M.
    Sankar, Vindira
    Ahlers, Christoph M.
    Salvati, Mark
    Wigginton, Jon M.
    Hellmann, Matthew D.
    Kollia, Georgia D.
    Gupta, Ashok K.
    Brahmer, Julie R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (18) : 2004 - U32
  • [8] Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
    Hamid, Omid
    Robert, Caroline
    Daud, Adil
    Hodi, F. Stephen
    Hwu, Wen-Jen
    Kefford, Richard
    Wolchok, Jedd D.
    Hersey, Peter
    Joseph, Richard W.
    Weber, Jeffrey S.
    Dronca, Roxana
    Gangadhar, Tara C.
    Patnaik, Amita
    Zarour, Hassane
    Joshua, Anthony M.
    Gergich, Kevin
    Elassaiss-Schaap, Jeroen
    Algazi, Alain
    Mateus, Christine
    Boasberg, Peter
    Tumeh, Paul C.
    Chmielowski, Bartosz
    Ebbinghaus, Scot W.
    Li, Xiaoyun Nicole
    Kang, S. Peter
    Ribas, Antoni
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (02) : 134 - 144
  • [9] Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
    Herbst, Roy S.
    Soria, Jean-Charles
    Kowanetz, Marcin
    Fine, Gregg D.
    Hamid, Omid
    Gordon, Michael S.
    Sosman, Jeffery A.
    McDermott, David F.
    Powderly, John D.
    Gettinger, Scott N.
    Kohrt, Holbrook E. K.
    Horn, Leora
    Lawrence, Donald P.
    Rost, Sandra
    Leabman, Maya
    Xiao, Yuanyuan
    Mokatrin, Ahmad
    Koeppen, Hartmut
    Hegde, Priti S.
    Mellman, Ira
    Chen, Daniel S.
    Hodi, F. Stephen
    [J]. NATURE, 2014, 515 (7528) : 563 - +
  • [10] CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans
    Huang, Rong Rong
    Jalil, Jason
    Economou, James S.
    Chmielowski, Bartosz
    Koya, Richard C.
    Mok, Stephen
    Sazegar, Hooman
    Seja, Elizabeth
    Villanueva, Arturo
    Gomez-Navarro, Jesus
    Glaspy, John A.
    Cochran, Alistair J.
    Ribas, Antoni
    [J]. CLINICAL CANCER RESEARCH, 2011, 17 (12) : 4101 - 4109